K. Kerr

发表

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

J. Austin, A. Nicholson, L. Chirieac, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

A. Nicholson, I. Petersen, I. Wistuba, 2013, Archives of pathology & laboratory medicine.

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.

L. Bubendorf, F. Herth, R. Rintoul, 2012, Lung cancer.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

Ashwini Naik, Allan Hackshaw, Zoltan Szallasi, 2017, Nature.

Tracking the Evolution of Non‐Small‐Cell Lung Cancer

Nicolai J. Birkbak, Z. Szallasi, M. Hayward, 2017, The New England journal of medicine.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Angela E. Leek, R. Booton, A. Nicholson, 2017, Cell.

PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project

F. Hirsch, K. Kerr, M. Tsao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Benjamin Solomon, Neal I. Lindeman, Dara L. Aisner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Oudkerk, P. Postmus, K. Kerr, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene Expression Profiling in Non-Small Cell Lung Cancer

Keith M. Kerr, Graeme I. Murray, K. Kerr, 2004, Clinical Cancer Research.

Idiopathic pulmonary fibrosis: an update.

K. Kerr, H. Remmen, L. Gomersall, 2006, QJM : monthly journal of the Association of Physicians.

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening

N J Wald, D M Hansell, D. Hansell, 2015, Thorax.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Gridelli, D. Ruysscher, K. Kerr, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, Archives of pathology & laboratory medicine.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center

N. Le Stang, N. Girard, A. Nicholson, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Closed pleural biopsy to diagnose mesothelioma: dead or alive?

K. Kerr, G. Currie, K. McLaughlin, 2009, Lung cancer.

Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Genetics.

Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society.

M. Mino‐Kenudson, M. Beasley, K. Kerr, 2018, Archives of pathology & laboratory medicine.

Alveolar proteinosis with hypersensitivity pneumonitis: A new clinical phenotype

A. Nicholson, D. Hansell, K. Kerr, 2010, Respirology.

Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries

K. Kerr, H. Popper, H. Mani, 2011, Journal of Clinical Pathology.

HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

K. Kerr, G. King, A. Kennedy, 1997, Journal of clinical pathology.

Hypoxia PET/CT and Colorectal Cancer: A Case Report

K. Kerr, G. Murray, M. Zanda, 2020 .

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.

R. Kaiser, K. Kerr, K. Syrigos, 2020, Lung cancer.

Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

P. Hegde, F. Hirsch, D. Gandara, 2017, Pneumologie.

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

L. Bubendorf, K. Kerr, W. Jochum, 2015, Lung cancer.

The Classification of Pre-invasive Lesions

K. Kerr, 2012 .

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening

D. Hansell, M. Parmar, T. Eisen, 2015, Thorax.

Pilot Screening Trial : baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening '

D. Hansell, M. Parmar, T. Eisen, 2016 .

Lung Cancer RCT Pilot Screening Trial : baseline fi ndings from the screening arm provide evidence for the potential implementation of lung cancer screening

D. Hansell, M. Parmar, T. Eisen, 2016 .

Atypical Adenomatous Hyperplasia, Lung

K. Kerr, A. Chapman, 2018 .

Adenocarcinoma In Situ

K. Kerr, A. Chapman, 2018 .

Minimally Invasive Adenocarcinoma (MIA)

K. Kerr, 2017 .

Molecular Pathology of Precursor and Pre-invasive Lesions

K. Kerr, 2012 .

Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases.

K. Kerr, D. Lamb, F. Carey, 1992, Thorax.

A clonal expression biomarker associates with lung cancer mortality

Angela E. Leek, Z. Szallasi, R. Booton, 2019, Nature Medicine.

Histological Appearances of Putative Montelukast Related Churg–strauss Syndrome Optimal Treatment for Idiopathic Pulmonary Fibrosis

K. Kerr, G. Currie, L. McKinlay, 2022 .

Relapsing necrotising sarcoid granulomatosis in a young patient

J. Legge, K. Kerr, G. Currie, 2007, European Respiratory Journal.

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.

John K Field, David R Baldwin, Anand Devaraj, 2016, Health technology assessment.

Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study

Iver Petersen, Elisabeth Brambilla, Ignacio Wistuba, 2012, Modern Pathology.

Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society.

A. Borczuk, M. Mino‐Kenudson, Y. Yatabe, 2016, Archives of Pathology & Laboratory Medicine.

Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression

K. Kerr, D. Lamb, F. Carey, 1994, The Journal of pathology.

UNITED KINGDOM LUNG CANCER SCREENING (UKLS) TRIAL

S. Duffy, D. Hansell, M. Parmar, 2011 .

Pulmonary adenocarcinomas: classification and reporting

K. Kerr, 2009, Histopathology.

Current issues in pulmonary adenocarcinoma

K. Kerr, 2008 .

Pathologist and molecular biologist, ever the twain shall meet?

K. Kerr, 2009, Lung cancer.

Morphology and genetics of pre-invasive pulmonary disease

K. Kerr, K. Kerr, 2004 .

Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†

K. Kerr, S. Peters, D. Fennell, 2015 .

Lymphohistiocytoid Variant of Malignant Mesothelioma of the Pleura: A Series of 22 Cases

F. Galateau-Sallé, K. Kerr, G. Launoy, 2007, The American journal of surgical pathology.

Abstract 3631: United Kingdom lung cancer screening trial (UKLS): First 88897 approaches.

S. Duffy, D. Hansell, M. Parmar, 2013 .

An audit of the clinical investigation of pleural effusion.

J. G. Douglas, J. Douglas, K. Kerr, 1992, Thorax.

A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.

K. Kerr, D. Lamb, 1988, British Journal of Cancer.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2019, Lung cancer.

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer

A. Rossi, K. Kerr, F. Morgillo, 2016, Current Oncology Reports.

Influence of tumour patterns in mixed-type adenocarcinoma on post-operative survival: P1-166

K. Kerr, M. Nicolson, N. Fyfe, 2007 .

Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens

K. Kerr, M. Nicolson, Keith M Kerr, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma.

K. Kerr, G. King, R. Jeffrey, 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study

Tuan S. Nguyen, P. Maxwell, K. Kerr, 2014, PloS one.

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

K. Kerr, C. Roberts, S. Edwards, 2000, Journal of clinical pathology.

Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma

K. Kerr, M. Nicolson, G. Murray, 2004, The Journal of pathology.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

A. Nicholson, A. Borczuk, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In vitro thymidine labelling of human pulmonary neoplasms.

K. Kerr, D. Lamb, A. M. Robertson, 1983, British Journal of Cancer.

Interobserver variation in the classification of thymic tumours – a multicentre study using the WHO classification system

A. Nicholson, B. Corrin, K. Kerr, 2008, Histopathology.

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Ming-Sound Tsao, Ignacio I Wistuba, A. Nicholson, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Notification of tuberculosis: can the pathologist help?

K. Kerr, D. Lamb, A. Leitch, 1988, BMJ.

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

A. Kent, N. Malats, G. Ciliberto, 2020, Cancers.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

S. Broderick, T. Mitsudomi, Changli Wang, 2021, Clinical Trials.

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

N. Girard, S. Broderick, T. Mitsudomi, 2021 .

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing In Non-Small Cell Lung Cancer.

R. Booton, L. Yarmus, M. Munavvar, 2020, Chest.

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

F. Hirsch, Keunchil Park, D. Gandara, 2021, Clinical lung cancer.

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management

K. Kerr, E. Thunnissen, F. Penault-Llorca, 2022, Virchows Archiv.

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

P. V. Van Schil, T. Mok, K. Kerr, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune cell infiltrates and prognosis in primary carcinoma of the lung.

K. Kerr, G. King, S. Johnson, 2000, Lung cancer.

Authors' response

S. Duffy, D. Hansell, T. Eisen, 2011, Thorax.

Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay

K. Kerr, E. Vokes, Hulin Jin, 2020 .

The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

K. Kerr, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease?

K. Kerr, O. Dempsey, J. Fiddes, 2007, European Respiratory Journal.

Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study.

K. Kerr, G. King, K. Blessing, 1996, The American Journal of dermatopathology.

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management

K. Kerr, E. Thunnissen, F. Penault-Llorca, 2022, Virchows Archiv.

Endobronchial lipoma associated with lobar bronchiectasis.

J. Douglas, K. Kerr, R. Jeffrey, 1991, Respiratory medicine.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

66 UK Lung Cancer Screening trial (UKLS): Prevalence data at baseline

S. Duffy, D. Hansell, R. Rintoul, 2014 .

Sarcoidosis

K. Kerr, O. Dempsey, A. Denison, 2009, BMJ : British Medical Journal.

Accelerated silicosis in Scottish stonemasons

J. Legge, K. Kerr, A. Seaton, 1991, The Lancet.

THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG

K. Kerr, D. Lamb, F. Carey, 1997, The Journal of pathology.

Guidelines on the radical management of patients with lung cancer

K. Kerr, C. Faivre-Finn, C. Warburton, 2010, Thorax.

Endobronchial ultrasound transbronchial needle aspiration at Aberdeen Royal Infirmary: the initial experience.

K. Kerr, M. Chetty, G. Currie, 2012, QJM : monthly journal of the Association of Physicians.

Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testing

A. Kent, N. Malats, G. Ciliberto, 2020 .

Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort

A. Warth, A. Marchetti, H. Moch, 2019 .

Mycobacterium microti infection associated with spindle cell pseudotumour and hypercalcaemia: a possible link with an infected alpaca

J. Douglas, K. Kerr, N. Smith, 2010, BMJ Case Reports.

The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

A. Nicholson, A. Borczuk, G. Scagliotti, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project

C. Dooms, L. Bubendorf, K. O'Byrne, 2012 .

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, K. Kerr, S. Peters, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

N. Le Stang, A. Borczuk, I. Wistuba, 2022, Journal of Thoracic Oncology.

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment

K. Kerr, E. Thunnissen, F. Penault-Llorca, 2022, Virchows Archiv.

Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue.

H. McLeod, K. Kerr, J. Kolesar, 2002, International journal of oncology.

Pleomorphic, spindle cell, and giant cell carcinoma

J. Austin, K. Kerr, G. Pelosi, 2015 .

Pathological and clinical investigation of pulmonary atypical adenomatous hyperplasia and its association with primary lung adenocarcinoma

K. Kerr, D. Thetford, A. Chapman, 2000 .

Killing of Aspergillus fumigatus spores by human lung macrophages: a paradoxical effect of heat-labile serum components.

K. Kerr, A. Seaton, M. D. Robertson, 1989, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Crispin J. Miller, Nicolai J. Birkbak, Angela E. Leek, 2019, Nature Medicine.

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

K. Kerr, F. López-Ríos, Keith M. Kerr, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Actual growth rate and tumour cell proliferation in human pulmonary neoplasms.

K. Kerr, D. Lamb, K. M. Kerr, 1984, British Journal of Cancer.

Prognostic factors in resected lung carcinomas

K. Kerr, M. Nicolson, 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

Partial regression in primary carcinoma of the lung: does it occur?

K. Kerr, G. King, S. Johnson, 1998, Histopathology.

Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms.

K. Kerr, D. Lamb, G. King, 1997, British Journal of Cancer.

Severe breathlessness, mouth ulcers and skin blistering in a female

K. Kerr, A. Ormerod, G. Devereux, 2004, European Respiratory Journal.

Cutaneous penile and perianal Crohn's disease treated with a combination of medical and surgical interventions

K. Kerr, A. Ormerod, S. Rajpara, 2008, The Australasian journal of dermatology.

Pulmonary Pathology

K. Kerr, P. Cagle, J. Krieken, 2018, Encyclopedia of Pathology.

Pachydermodactyly: confused with JCA.

K. Kerr, J. C. Martin, J. Rennie, 1992, Annals of the rheumatic diseases.

Characterization of Salmonella hadar

K. Kerr, E. R. Richter, F. Muir, 2013 .

Control of infectious synovitis. 12. Preparation of an agglutination test antigen.

K. Kerr, A. Campbell, N. O. Olson, 1963, Avian diseases.

CONTROL OF INFECTIOUS SYNOVITIS 13. THE ANTIGEN STUDY OF

K. Kerr, A. Campbell, N. O. Olson, 1964 .

RAPID SPECIFIC AGGLUTINATION OF EATON AGENT (MYCOPLASMA PNEUMONIAE)

K. Kerr, C. Mascoli, A. Campbell, 1964, Journal of bacteriology.

Lecce (12) found infectious-synovitis-derived pleuro- pneumonia-like organisms (ISD-PPLO) colonies growing as

K. Kerr, A. Campbell, N. O. Olson, 2016 .

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Angela E. Leek, R. Booton, A. Nicholson, 2018, Cancer cell.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Akihiko Yoshida, Mari Mino-Kenudson, Arne Warth, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

M. Slade, K. Kerr, S. Tsim, 2018, Thorax.

HBME-1andantithrombomodulin inthe differential diagnosis ofmalignant mesothelioma ofpleura

K. Kerr, G. King, A. Kennedy, 1997 .

Metastatic pulmonary ameloblastoma. An unusual case.

K. Kerr, F. Wallis, R. Jeffrey, 2003, The British journal of oral & maxillofacial surgery.

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

A. Kent, N. Malats, G. Ciliberto, 2020, Biomedicine Hub.

Hydroxycarbamide‐induced pneumonitis

K. Kerr, E. Husain, P. S. Loo, 2009, Histopathology.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

I. Wistuba, F. Hirsch, D. Rimm, 2021, Nature Reviews Clinical Oncology.

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of Thoracic Oncology.

PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.

N. Girard, A. Nicholson, A. Borczuk, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society.

A. Borczuk, M. Mino‐Kenudson, Y. Yatabe, 2016, Archives of pathology & laboratory medicine.

EGFR Mutation Testing Practices within the Asia Pacific Region

S. Toyooka, Y. Yatabe, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, E. Smit, T. Mok, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoantigen-directed immune escape in lung cancer evolution

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2019, Nature.

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

K. Kerr, R. Doebele, D. Camidge, 2019, Nature Reviews Clinical Oncology.

Using DNA sequencing data to quantify T cell fraction and therapy response

Angela E. Leek, Z. Szallasi, R. Booton, 2021, Nature.

Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

K. Kerr, E. Thunnissen, J. Wolf, 2021, Lung cancer.

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of Thoracic Oncology.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy

K. Kerr, G. Laing, 2018 .

PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.

K. Kerr, R. Stahel, S. Peters, 2018, Cancer treatment reviews.

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

K. Bloom, M. Dietel, K. Kerr, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

A. Borczuk, M. Mino‐Kenudson, Y. Yatabe, 2016, Archives of pathology & laboratory medicine.

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

F. Hirsch, K. Kerr, 2016, Archives of pathology & laboratory medicine.

The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma

P. Laird, K. Kerr, I. Laird-Offringa, 2007, Disease markers.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

F. Hirsch, K. Kerr, E. Van Cutsem, 2013, European journal of cancer.

DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma

Kimberly D. Siegmund, Keith M. Kerr, Mihaela Campan, 2011, PloS one.

Thyroid transcription factor 1 in pulmonary adenocarcinoma

K. Kerr, G. King, N. Fyfe, 2004, Journal of Clinical Pathology.

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

A. Nicholson, K. Kerr, D. Moore, 2021, British Journal of Cancer.

Geospatial immune variability illuminates differential evolution of lung adenocarcinoma

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Medicine.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

A. Marchetti, M. Dietel, L. Bubendorf, 2016, Virchows Archiv.

BTS guideline for the investigation and management of malignant pleural mesothelioma

M. Slade, K. Kerr, S. Tsim, 2018, BMJ Open Respiratory Research.

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer

K. O'Byrne, K. Kerr, F. Shepherd, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Mark Cobbold, Iftekhar Khan, Caroline Dive, 2014, PLoS biology.

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

Peter Schmid, Marcin Skrzypski, Allan Hackshaw, 2019, Nature Medicine.

The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.

Edward S. Kim, M. Tsuboi, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

I. Wistuba, M. Mino‐Kenudson, F. Hirsch, 2022 .

A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens

F. Cappuzzo, L. Bubendorf, K. Kerr, 2020, Cancer cytopathology.

PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project

Hui Yu, Keith M. Kerr, Ignacio Wistuba, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Precision Molecular Pathology of Lung Cancer

A. Borczuk, L. Chirieac, M. Beasley, 2017, Molecular Pathology Library.

ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen

P. Maxwell, K. Kerr, E. Thunnissen, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

T. Molina, A. Marx, K. Kerr, 2013, Archives of pathology & laboratory medicine.

Expression of CD44v6 but not E‐cadherin or β‐catenin influences prognosis in primary pulmonary adenocarcinoma

K. Kerr, G. King, R. Jeffrey, 2000, The Journal of pathology.

Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy

K. Kerr, P. Hasleton, H. Anderson, 2005, Histopathology.

Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

C. Dooms, K. Nackaerts, A. Warth, 2019, Modern Pathology.

OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study

A. Nicholson, A. Borczuk, L. Chirieac, 2018, Journal of Thoracic Oncology.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

M Dietel, M. Dietel, K. Kerr, 2014, British Journal of Cancer.

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC

K. O'Byrne, K. Kerr, R. Pirker, 2011, Journal of Clinical Pathology.

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

Michael Thomas, Federico Cappuzzo, Manfred Dietel, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2022, Nature Cancer.

The T cell differentiation landscape is shaped by tumour mutations in lung cancer

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Cancer.

PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples

Keith M. Kerr, F. Hirsch, Y. Yatabe, 2017 .

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.

L. Bubendorf, Y. Yatabe, P. Illei, 2021, Lung cancer.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

A. Marchetti, L. Bubendorf, K. O'Byrne, 2014 .

Precision Medicine in Lung Cancer

K. Kerr, G. Laing, 2018 .

Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

K. Kerr, M. Nicolson, Keith M Kerr, 2016, Archives of pathology & laboratory medicine.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

G. Wainrib, P. Courtiol, C. Maussion, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer.

N. Le Stang, A. Nicholson, A. Borczuk, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cytology for PD-L1 testing: A systematic review.

K. Kerr, J. Gosney, A. Boothman, 2020, Lung cancer.

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

P. V. Van Schil, E. Smit, K. Kerr, 2020, The oncologist.

Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer.

K. Kerr, D. Bissett, M. Nicolson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Oudkerk, S Senan, M. Oudkerk, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas

A. Nicholson, K. Kerr, M. Freidin, 2014, Histopathology.

The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification

J. Austin, A. Nicholson, I. Petersen, 2009 .

Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer.

A. Nicholson, K. Kerr, E. Thunnissen, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathology and personalized medicine in lung cancer

K. Kerr, M. Nicolson, P. S. Loo, 2013 .

ALK testing in non-small cell lung carcinoma: what now?

K. Kerr, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee.

A. Nicholson, A. Borczuk, W. Travis, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study

A. Nicholson, I. Petersen, L. Chirieac, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

A. Hofman, S. Cajal, P. Brousset, 2020, ESMO Open.

Necrotizing sarcoid granulomatosis with extrapulmonary involvement.

C. C. Smith, K. Kerr, M. Kennedy, 1997, The European respiratory journal.

Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.

H. McLeod, K. Kerr, J. McKay, 2001, Oncology reports.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D De Ruysscher, N. Reinmuth, D. de Ruysscher, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization

L. Bubendorf, E. Schuuring, K. Kerr, 2014, PloS one.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

A. Warth, A. Marchetti, L. Bubendorf, 2017, Lung cancer.

Personalized medicine for lung cancer: new challenges for pathology

K. Kerr, 2012, Histopathology.

Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy

K. Kerr, E. Yi, Jin-Haeng Chung, 2012, Molecular Diagnosis & Therapy.

Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.

K. Kerr, Jin-Haeng Chung, K. Kulig, 2012, Molecular diagnosis & therapy.

Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.

K. Kerr, A. Khankan, T. Slavik, 2014, Clinical lung cancer.

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis

J. Johnston, K. Kerr, D. Fennell, 2013, Oncotarget.

Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

T. Mok, K. Kerr, G. Veronesi, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

C. Dooms, A. Marchetti, L. Bubendorf, 2014 .

Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?

Keith Kerr, R. Booton, K. Kerr, 2011, Thorax.

Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort

A. Warth, A. Marchetti, H. Moch, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

M. Mino‐Kenudson, Y. Yatabe, M. Beasley, 2016, Archives of pathology & laboratory medicine.

Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

A. Nicholson, I. Petersen, I. Wistuba, 2013, Archives of pathology & laboratory medicine.

Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer

T. Mok, K. Kerr, M. Reck, 2019, Clinical Cancer Research.

Spontaneous dissection of an anomalous systemic artery in the lung during pregnancy: a rare cause of hemoptysis.

K. Kerr, H. Remmen, R. Saad, 2006, The Annals of thoracic surgery.

The association between atypical adenomatous hyperplasia and primary lung cancer

K. Kerr, A. Chapman, 2000, British Journal of Cancer.

Inflammatory endobronchial polyposis with bronchiectasis in cystic fibrosis.

K. Kerr, A. Devenny, C. Roberts, 2001, The European respiratory journal.

Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria

A. Nicholson, D. Yankelevitz, I. Wistuba, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

Nicolai J. Birkbak, Angela E. Leek, R. Booton, 2017, Immunity.

Iron lung: bronchoscopic and pathological consequences of aspiration of ferrous sulphate.

J. Legge, K. Kerr, D. Godden, 1991, Thorax.

Pulmonary preinvasive neoplasia

K. Kerr, 2001, Journal of clinical pathology.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, The Journal of molecular diagnostics : JMD.

Mixed Squamous Cell and Glandular Papilloma

K. Kerr, R. Miller, 2017 .

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

R. Kaiser, N. Pavlakis, Keunchil Park, 2019, Future oncology.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

D. Ettinger, F. Cappuzzo, E. Smit, 2016, ESMO Open.

PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer

P. Hamilton, K. O'Byrne, K. Kerr, 2011, The Journal of pathology.

How to investigate a patient with suspected interstitial lung disease

K. Kerr, H. Remmen, O. Dempsey, 2010, BMJ : British Medical Journal.

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

K. Kerr, J. V. van Meerbeeck, F. Penault-Llorca, 2022, Journal of personalized medicine.

Calcified pulmonary chondromas in Carney's triad

H. Haja Mydin, K. Kerr, O. Dempsey, 2013, Thorax.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation

R. Booton, A. Nicholson, K. Kerr, 2016, Histopathology.

Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Genetics.

Quantitative Analysis of Tumor in Bronchial Biopsy Specimens

K. Kerr, M. Nicolson, G. Devereux, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2018 .

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

C. Dooms, M. Dietel, L. Bubendorf, 2015, Thorax.

Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

C. Dooms, K. Nackaerts, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria

H. Höfler, D. Aust, A. Warth, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

M. Dietel, H. Moch, L. Bubendorf, 2012, Virchows Archiv.

Pulmonary veno-occlusive disease complicating Felty's syndrome.

J. Legge, K. Kerr, G. Devereux, 1998, Respiratory medicine.

Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Medicine.

The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening

John K Field, David R Baldwin, Anand Devaraj, 2014, Cancer Prevention Research.

Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification

K. Kerr, 2013, Journal of Clinical Pathology.

Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial

Tuan S. Nguyen, K. O'Byrne, K. Kerr, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inter-observer variation between pathologists in diffuse parenchymal lung disease

B J Addis, H Bharucha, A. Nicholson, 2004, Thorax.

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.

A. Nicholson, D. Yankelevitz, I. Wistuba, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee.

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Merkel cell and squamous cell carcinomas arising in erythema ab igne

K. Kerr, A. Sherif, L. Stankler, 1993, The British journal of dermatology.

A comparison of cobalt (57Co) bleomycin scanning and contrast-enhanced CT scanning for assessment of the mediastinum in lung cancer.

J. Best, K. Kerr, N. Douglas, 1990, Chest.

Changing trends in incidence of lung cancer by histologic type in Scotland

K. Kerr, G. Macfarlane, E. Harkness, 2002, International journal of cancer.

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

A. Marchetti, L. Bubendorf, U. Dafni, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis

S. Duffy, M. Parmar, T. Eisen, 2021, The Lancet regional health. Europe.

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

N. Girard, S. Broderick, T. Mitsudomi, 2022, Cancer Research.

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.

R. Booton, K. Kerr, F. Blackhall, 2013, Lung cancer.

Survival from malignant mesothelioma: where are we now?

K. Kerr, H. Bayes, G. Currie, 2015, The journal of the Royal College of Physicians of Edinburgh.

A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee.

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An investigation into the role of human papillomavirus in endobronchial papillary squamous tumours.

K. Kerr, D. Lamb, F. Carey, 1990, Respiratory medicine.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Ashwini Naik, Allan Hackshaw, Zoltan Szallasi, 2017, Nature.

Lung adenocarcinoma promotion by air pollutants

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2023, Nature.

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Angela E. Leek, Robin L. Jones, Z. Szallasi, 2023, Nature.

Genomic–transcriptomic evolution in lung cancer and metastasis

Angela E. Leek, Z. Szallasi, A. Nicholson, 2023, Nature.

Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx

David R. Jones, Angela E. Leek, Z. Szallasi, 2023, Nature Medicine.

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Angela E. Leek, Z. Szallasi, A. Nicholson, 2023, Nature.

The evolution of lung cancer and impact of subclonal selection in TRACERx

Nicolai J. Birkbak, Angela E. Leek, D. M. Miedema, 2023, Nature.

The evolution of non-small cell lung cancer metastases in TRACERx

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2023, Nature.

Classification of lung cancer: proposals for change?

K. Kerr, 2012, Archives of pathology & laboratory medicine.

EU–USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer

C. Comin, E. Brambilla, D. Flieder, 2006, European Respiratory Journal.

Body composition and lung cancer-associated cachexia in TRACERx

Angela E. Leek, N. Perrimon, Z. Szallasi, 2023, Nature Medicine.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

A. Nicholson, A. Marchetti, L. Bubendorf, 2020, Archives of pathology & laboratory medicine.

P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer

A. Nicholson, A. Borczuk, Guoan Chen, 2019, Journal of Thoracic Oncology.

PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay.

K. Kerr, E. Vokes, Hulin Jin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Personalized cancer medicine and the future of pathology

M. Dietel, H. Moch, K. Kerr, 2011, Virchows Archiv.

Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected Samples

R. Booton, M. Lindsay, K. Kerr, 2017, Respiratory Research.

Primary pulmonary osteosarcoma

H. McLeod, K. Kerr, M. Nicolson, 2001, Cancer.

Revolution in lung cancer: new challenges for the surgical pathologist.

Philip T Cagle, A. Borczuk, L. Chirieac, 2011, Archives of pathology & laboratory medicine.

Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging.

K. Kerr, N. Douglas, D. Lamb, 1992, Thorax.

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.

I. Wistuba, M. Mino‐Kenudson, F. Hirsch, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions

K. Kerr, M. Peake, J. Gosney, 2023, Journal of clinical pathology.

P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC

S. Broderick, T. Mitsudomi, K. Kerr, 2018, Journal of Thoracic Oncology.

Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer

K. Kerr, M. Nicolson, R. Petty, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer.

H. McLeod, K. Kerr, M. Nicolson, 2000, Cancer research.

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.

Y. Yatabe, M. Ahn, K. Kerr, 2023, Lung cancer.

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.

P. Jänne, I. Wistuba, K. Kerr, 2023, ESMO open.

MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists

A. Nicholson, K. Kerr, E. Thunnissen, 2018, Journal of Thoracic Oncology.

Molecular pathology of lung cancer

A. Borczuk, L. Chirieac, M. Beasley, 2012 .

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung

A. Nicholson, A. Borczuk, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report

S. Duffy, D. Hansell, M. Parmar, 2011, Thorax.

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

C. Dooms, A. Marchetti, K. Syrigos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Histological diagnosis: recent developments

K. Kerr, L. Smart, A. Chapman, 2015 .

3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2015 .

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

N. Girard, S. Broderick, K. Kerr, 2017 .

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

S Senan, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

P Baas, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Mucoepidermoid Carcinoma, Lung

K. Kerr, 2017 .

The 2015 World Health Organisation Classification of Lung Cancer

K. Kerr, G. Laing, 2018 .

Details of the Liverpool Lung Project risk model (version 2)

Stephen W. Duffy, David K. Whynes, John K Field, 2016 .

Revised Classification for Adenocarcinoma

K. Kerr, P. Cagle, 2012 .

Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project

A. Warth, H. Dienemann, A. Marchetti, 2015 .

Tuberculosis of the trachea.

K. Kerr, A. Douglas, C. Wathen, 1987, Tubercle.

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

A. Nicholson, A. Borczuk, I. Wistuba, 2020 .

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

A. Marchetti, M. Dietel, L. Bubendorf, 2016, Virchows Archiv.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.

K. Kerr, A. Khankan, T. Slavik, 2014, Clinical lung cancer.

Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.

A. Warth, A. Marchetti, L. Bubendorf, 2017 .

PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer

P. Hamilton, K. O'Byrne, K. Kerr, 2011, The Journal of pathology.

Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.

F. Cappuzzo, R. Herbst, T. Mitsudomi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

C. Dooms, M. Dietel, L. Bubendorf, 2015, Thorax.